5-hydroxypropafenone has been researched along with debrisoquin in 3 studies
| Studies (5-hydroxypropafenone) | Trials (5-hydroxypropafenone) | Recent Studies (post-2010) (5-hydroxypropafenone) | Studies (debrisoquin) | Trials (debrisoquin) | Recent Studies (post-2010) (debrisoquin) |
|---|---|---|---|---|---|
| 59 | 3 | 3 | 890 | 89 | 17 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Belloni, M; Bernasconi, R; Cappiello, E; Castel, JM; Giani, P; Landolina, M; Latini, R; Leopaldi, D | 1 |
| Ambrosioni, E; Balducelli, M; Boriani, G; Capucci, A; Frabetti, L; Magnani, B; Marchesini, B; Strocchi, E; Tomasi, L | 1 |
| McAllister, CB; Roden, DM; Siddoway, LA; Thompson, KA; Wang, T; Wilkinson, GR; Woosley, RL | 1 |
3 other study(ies) available for 5-hydroxypropafenone and debrisoquin
| Article | Year |
|---|---|
Identification of propafenone metaboliser phenotype from plasma and urine excretion data.
Topics: Adolescent; Adult; Aged; Arrhythmias, Cardiac; Child; Debrisoquin; Female; Humans; Hydroxylation; Male; Middle Aged; Phenotype; Propafenone | 1992 |
Minimal effective concentration values of propafenone and 5-hydroxy-propafenone in acute and chronic therapy.
Topics: Administration, Oral; Adult; Aged; Debrisoquin; Dose-Response Relationship, Drug; Electrocardiography; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Phenotype; Propafenone; Time Factors | 1990 |
Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences.
Topics: Adult; Aged; Arrhythmias, Cardiac; Cytochrome P-450 CYP2D6; Debrisoquin; Dose-Response Relationship, Drug; Drug Evaluation; Female; Humans; In Vitro Techniques; Kinetics; Liver; Male; Middle Aged; Mixed Function Oxygenases; Phenotype; Propafenone; Time Factors | 1987 |